Literature DB >> 21384270

Hypocellularity and insufficient expression of angiogenic factors in implanted autologous bone marrow in patients with chronic critical limb ischemia.

Masato Oda1, Ken Toba, Kiminori Kato, Takuya Ozawa, Takao Yanagawa, Noboru Ikarashi, Tsugumi Takayama, Tomoyasu Suzuki, Haruo Hanawa, Masayoshi Masuko, Hironori Kobayashi, Yoshifusa Aizawa.   

Abstract

The aim of this study was to identify the clinical parameters of absolutely poor-prognosis patients with chronic critical limb ischemia (AP-CLI). Sixteen no-option CLI patients with arteriosclerosis obliterans: ASO (nine) and non-ASO patients (seven) treated with bone marrow-mononuclear cell implantation (BMI) were analyzed. There were three AP-CLI patients (all ASO). The mRNA expression of several angiogenic factors in the implanted cells was analyzed in comparison with normal donor bone marrow. To observe the response of bone marrow components to hypoxia, normal bone marrow cells were cultured for 24 h in 2.5% O(2), and mRNA expression of angiogenic factors were measured. AP-CLI patients exhibited extraordinary low bone marrow cellularity as well as the percentage of CD34-positive cells. Among angiogenic factors, only VEGF expression was maintained in response to HIF-1, while other factors such as HGF, Ang-1, PLGF, and SDF-1 decreased in the implanted bone marrow cells of the patients with CLI compared to normal bone marrow cells. HIF-1 and all of the five angiogenic factors increased in vitro in response to hypoxia. Thus it is highly likely that angiogenic factors except VEGF do not respond to chronic ischemia in bone marrow in vivo. An organ-protection system against tissue ischemia may be applied for acute hypoxia, but it may be insufficient for chronic ischemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21384270     DOI: 10.1007/s00380-011-0125-5

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  37 in total

1.  Neutrophil and erythroblast regulate the effects of bone marrow cell implantation.

Authors:  H Suzuki; Y Iso; T Kusuyama; Y Omori; T Soda; T Sato; M Shoji; S Koba; E Geshi; T Katagiri
Journal:  Eur J Clin Invest       Date:  2006-01       Impact factor: 4.686

2.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

3.  Different angiogenesis effect of mini-TyrRS/mini-TrpRS by systemic administration of modified siRNAs in rats with acute myocardial infarction.

Authors:  Rui Zeng; Yu-Cheng Chen; Zhi Zeng; Wei-Qiang Liu; Xiao-Xia Liu; Rui Liu; Ou Qiang; Xian Li
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

4.  Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation.

Authors:  Takuya Ozawa; Ken Toba; Kiminori Kato; Shiro Minagawa; Takashi Saigawa; Haruo Hanawa; Yashiro Makiyama; Masato Moriyama; Kei-Ichiro Honma; Manabu Isoda; Go Hasegawa; Makoto Naito; Masuhiro Takahashi; Yoshifusa Aizawa
Journal:  J Mol Cell Cardiol       Date:  2006-05       Impact factor: 5.000

5.  Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb.

Authors:  J M Isner; A Pieczek; R Schainfeld; R Blair; L Haley; T Asahara; K Rosenfield; S Razvi; K Walsh; J F Symes
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

Review 6.  Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling.

Authors:  Sergio Rey; Gregg L Semenza
Journal:  Cardiovasc Res       Date:  2010-02-17       Impact factor: 10.787

7.  Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.

Authors:  Sanjay Rajagopalan; Emile R Mohler; Robert J Lederman; Farrell O Mendelsohn; Jorge F Saucedo; Corey K Goldman; John Blebea; Jennifer Macko; Paul D Kessler; Henrik S Rasmussen; Brian H Annex
Journal:  Circulation       Date:  2003-09-22       Impact factor: 29.690

8.  Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.

Authors:  Ryuichi Morishita; Motokuni Aoki; Naotaka Hashiya; Hirofumi Makino; Keita Yamasaki; Junya Azuma; Yoshiki Sawa; Hikaru Matsuda; Yasufumi Kaneda; Toshio Ogihara
Journal:  Hypertension       Date:  2004-07-06       Impact factor: 10.190

9.  Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study).

Authors:  T Bartsch; M Brehm; T Zeus; G Kögler; P Wernet; B E Strauer
Journal:  Clin Res Cardiol       Date:  2007-08-17       Impact factor: 5.460

10.  Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease.

Authors:  Antonio Liguori; Carmela Fiorito; Maria Luisa Balestrieri; Ettore Crimi; Giuseppe Bruzzese; Sharon Williams-Ignarro; Maurizio D'Amora; Linda Sommese; Vincenzo Grimaldi; Pellegrino Biagio Minucci; Alfonso Giovane; Bartolomeo Farzati; Louis J Ignarro; Claudio Napoli
Journal:  Eur J Haematol       Date:  2007-12-07       Impact factor: 2.997

View more
  3 in total

1.  Clinical significance of Angiopoietin-1 in Behcet's disease patients with vascular involvement.

Authors:  Iman H Bassyouni; Mohammed Sharaf; Iman E Wali; Hossam M Mansour
Journal:  Heart Vessels       Date:  2015-05-12       Impact factor: 2.037

2.  Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients.

Authors:  Martin Teraa; Ralf W Sprengers; Peter E Westerweel; Hendrik Gremmels; Marie-José T H Goumans; Tom Teerlink; Frans L Moll; Marianne C Verhaar
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

3.  Effect of sarpogrelate treatment on the prognosis after endovascular therapy for critical limb ischemia.

Authors:  Mitsuyoshi Takahara; Hideaki Kaneto; Naoto Katakami; Osamu Iida; Taka-Aki Matsuoka; Iichiro Shimomura
Journal:  Heart Vessels       Date:  2013-03-14       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.